CVRx, Inc. (NASDAQ:CVRX)
| Market Cap | $14.27M-94.9% |
| Revenue (ttm) | $60.33M+7.8% |
| Net Income | -$53.26M-2.4% |
| EPS | -$2.01+0.5% |
| Shares Out | 28.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 519,859 |
| Open | $0.55 |
| Previous Close | $0.53 |
| Day's Range | $0.50 - $0.56 |
| 52-Week Range | $0.50 - $10.28 |
| Beta | 0.76 |
| Analysts | Buy |
| Price Target | $3.70(+638.52%) |
| Earnings Date | Feb 11, 2027 |
About CVRX
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating CVRX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 11, 2027Earnings report
$CVRX stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of CVRX by members of U.S. Congress
| Richard BlumenthalSenate / D | Sale$1.00K – $15.00K | Jul 8, 2026 |
Recently reported changes in CVRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CVRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CVRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CVRX Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CVRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CVRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CVRX
| VTIVanguard Morningstar Total Stock Market ETF | $705.07K |
| VXFVanguard Extended Market ETF | $288.39K |
| IWMiShares Russell 2000 ETF | $199.67K |
| VTWOVanguard Russell 2000 ETF | $126.48K |
| IWOiShares Russell 2000 Growth ETF | $84.30K |
| IWCiShares Micro-Cap ETF | $24.97K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CVRX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.02% |
Weight is the stock’s share of each fund’s holdings.
